Cocrystal Pharma, Inc. (COCP) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
August 15, 2022 8:00 AM EDTPlanned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its Phase 1 study with CC-42344 supporting once-daily dosingCollaborated with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of the Companys COVID-19 protease inhibitors and subsequently expanded the collaboration to support a scale-up synthesis of these inhibitorsInitiated API (Active Pharmaceutical Ingredient) synthesis and process chemistry... More
